Results 201 to 210 of about 89,390 (263)

Safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled hypertension: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Kamrul-Hasan ABM, Chatterjee S, Nagendra L, Nair S, Dutta D, Pappachan JM.   +5 more
europepmc   +1 more source

Familial Hyperaldosteronism Type IV (FH-IV)-Clinical Phenotypes, Genetics and Management of <i>CACNA1H</i>-Related Primary Aldosteronism: A Systematic Review. [PDF]

J Clin Med
Michalski W, Jaszczyszyn I, Bielska W, Stolarczyk A.   +3 more
europepmc   +1 more source

Baxdrostat: A First-in-Class Aldosterone Synthase Inhibitor for Resistant Hypertension. [PDF]

ACS Pharmacol Transl Sci
Capriello I, Dömling A.
europepmc   +1 more source

Spironolactone or Finerenone for Cardiovascular and Kidney Protection in Patients with Moderate CKD? [PDF]

Am J Cardiovasc Drugs
Georgianos PI, Leptokaridou-Mourtzila E, Kourtidou C, Kontogiorgos I, Roumeliotis A, Vaios V, Liakopoulos V.   +6 more
europepmc   +1 more source

A Neonatal Salt-Wasting Crisis Mimicking Congenital Adrenal Hyperplasia: A Case of Transient Pseudohypoaldosteronism. [PDF]

Cureus
Abdulsalam TA, Obaisi TA.
europepmc   +1 more source

ALDOSTERONE AND ALDOSTERONE ANTAGONISTS.

North Carolina medical journal, 1996
openaire   +1 more source

Unmasking Hormonal Mechanisms of Hypertension in Obesity. [PDF]

JACC Basic Transl Sci
Parisien-La Salle S, Tsai CH, Newman AJ, Chan JM, Milks J, Adler G, Ferrebus A, Hanna I, Mahrokhian S, Pitt B, Brown JM, Vaidya A.   +11 more
europepmc   +1 more source

Comment on ‘Clinical Presentation and Early Outcomes of Congenital Endocrine Salt‐Wasting Syndromes Unrelated to 21‐Hydroxylase Deficiency’

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Gulalai Tariq, Muhammad Faizan Khan, Malghalara   +2 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aldosterone, Renin, and Aldosterone-to-Renin Ratio Variability in Screening for Primary Aldosteronism

The Journal of Clinical Endocrinology & Metabolism, 2022
Abstract Context The plasma aldosterone concentration (PAC), renin, and aldosterone-to-renin ratio (ARR) are used to screen for primary aldosteronism (PA). Substantial intra-individual variability of PAC and ARR using plasma renin activity in the context of usual antihypertensive therapy has been ...
Elisabeth Ng, Stella May Gwini, Renata Libianto, Kay Weng Choy, Zhong X Lu, Jimmy Shen, James C G Doery, Peter J Fuller, Jun Yang   +8 more
openaire   +2 more sources